Meeting
2022 ASCO Annual Meeting
Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Authors
Matthew J. Matasar
Memorial Sloan Kettering Cancer Center, New York, NY
Matthew J. Matasar , Corinne Haioun , Juan-Manuel Sancho , Andreas Viardot , Antonia Rodriguez Izquierdo , Eva Maria Donato Martin , Alejandro Martin Garcia-Sancho , Jose David Sandoval-Sus , Herve Tilly , Elizabeth Vandenberghe , Jamie Hirata , Priya Choudhry , Yi Meng Chang , Lisa Musick , Andrew McMillan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT04182204
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7551)
DOI
10.1200/JCO.2022.40.16_suppl.7551
Abstract #
7551
Poster Bd #
204
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
First Author: Mark Hertzberg
Poster
2021 ASCO Annual Meeting
Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.
First Author: Mehdi Hamadani
Poster
2022 ASCO Annual Meeting
Phase 3 randomized study of loncastuximab tesirine in combination with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL (LOTIS-5).
First Author: Mehdi Hamadani